buprenorphine hydrochloride · Indivior · NDA 020732
Subutex
Earliest generic entry, as listed · earliest of 2 marketed strengths
Open now
No marketed reference-listed strength; date taken from all listed strengths.
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 25 Oct 2026Generic approved · 020732-00210 Dec 2025
- 25 Oct 2026Generic approved · 020732-00218 Dec 2025
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 020732 · 002 · RLD · discontinued | tablet, sublingual | EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 020732 · 003 · RLD · discontinued | tablet, sublingual | EQ 8MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |